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Abstract
Background: Parkinson’s disease (PD) is a chronic progressive disorder leading to increasing disability. While the
symptoms and needs of patients in the early stages of their disease are well characterized, little information is
available on patients in the late stage of the disease.
Methods/design: The Care of Late-Stage Parkinsonism (CLaSP) study is a longitudinal, multicenter, prospective
cohort study to assess the needs and provision of care for patients with late stage Parkinsonism and their carers in
six European countries (UK, France, Germany, Netherlands, Portugal, Sweden). In addition, it will compare the
effectiveness of different health and social care systems. Patients with Parkinsonism with Hoehn and Yahr stage ≥IV
in the “On”-state or Schwab and England stage 50% or less are evaluated at baseline and three follow-up time-
points. Standardised questionnaires and tests are applied for detailed clinical, neuropsychological, behavioural and
health-economic assessments. A qualitative study explores the health care needs and experiences of patients
and carers, and an interventional sub-study evaluates the impact of specialist recommendations on
their outcomes.
Discussion: Through the combined assessment of a range of quantitative measures and qualitative
assessments of patients with late stage parkinsonism, this study will provide for the first time comprehensive
and in-depth information on the clinical presentation, needs and health care provision in this population in
Europe, and lay the foundation for improved outcomes in these patients.
Trial registration: The protocol was registered at ClinicalTrials.gov as NCT02333175 on 07/01/2015.
Keywords: Late stage parkinsonism, Care provision, Non-motor complications, Quality of care, Health-related
quality of life, Health-economic evaluation, Patient-reported outcomes
Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder, affecting approximately 1.2
million people in Europe [1]. There is increasing disabil-
ity with disease progression, but whilst there is an abun-
dant number of studies on the health and social care
needs of patients in the early stages of PD, there is sur-
prisingly little information on the medical and care
needs of the late stage population, and how these needs
are currently met. In addition, there is little information
on the use and effectiveness of the pharmacological and
non-pharmacological interventions for PD in these late
stages, when there may be multiple features and comor-
bidities. These include motor complications and non-
motor symptoms such as behavioral and psychological
symptoms, autonomic disturbances and sleep disorders,
which can contribute to the burden of the disease to
patients and their carers [2, 3] and may lead to nursing
home placement and higher mortality [3–5]. Most stud-
ies on the management and care needs of patients with
PD include only small subgroups in the late stages of the
disease [6, 7] and patients in Hoehn and Yahr stages IV
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and V [8] are usually excluded from clinical trials [9]. In
specialist practice, the proportion of patients in the late
stages is also underrepresented as they are often too dis-
abled to attend hospital or office-based appointments
and do not receive adequate care [10]. It is therefore
currently relatively unknown what the exact health care
needs are in patients with late stage Parkinsonism, and
no large study has evaluated the provision of health care
for these patients and associated costs across different
European health care systems. Small studies point to an
increased use of health as well as social care resources
(hospitalization and institutionalization) in late PD
stages [11–14] and a high need for informal care with
increased caregiver burden [12, 14].
The Care of Late-Stage Parkinsonism (CLaSP) study
aims to establish a large European cohort of patients
with parkinsonism in the late stage of the disease (i.e.
HY stages IV/V in the “On”-stage or Schwab and Eng-
land stage 50% or less) in six European countries to
examine the health and social care needs of this patient
group and their carers, available health care provision
and costs to society. Alongside the cohort study, eligible
patients are randomised in an interventional trial evalu-
ating the impact of specialist recommendations in pa-
tients in late stages of Parkinsonism, and a qualitative
study explores the health care needs and experiences of
patients and carers. This article describes in detail the
methodology of the study and the assessments used in
this large and unique cohort. An abstract on the study
design has been previously published [15].
Methods
Study design
The CLaSP study is a longitudinal multicenter cohort
study of patients with late stage Parkinsonism and their
carers. In the six European health care systems (London
and Luton, UK; Marburg-Giessen, Essen, and Munich,
Germany; Nijmegen, The Netherlands; Bordeaux, France;
Lisbon, Portugal; and Lund, Sweden) patients with
late-stage Parkinsonism and their informal carers are
identified from neurology, care of the elderly, palliative
care, and primary care settings. Patients for the qualitative
interviews and for the intervention trial are recruited from
the participants in the cohort study.
Cohort study
Inclusion criteria
Patients are eligible for enrolment in the CLaSP study, if
they had been diagnosed for at least seven years with
Parkinsonism and are classified as Hoehn and Yahr stage
(HY) IV or V in the “On”-state OR have developed sig-
nificant disability (Schwab and England stage ≤50%) in
the “On”-state [16]. Established clinical criteria (UK Par-
kinson's Disease Society Brain Bank Diagnostic Criteria
[17]) are applied to distinguish subjects with PD from
those with different atypical parkinsonian syndromes.
However, since distinction in late stages of the disease
can be difficult and patient needs are likely to be similar
despite different underlying pathology, patients with
atypical parkinsonian disorders are not excluded.
Exclusion criteria
Patients with PD in HY stages I-III are excluded as well
as patients with a diagnosis of “symptomatic PD” such
as normal pressure hydrocephalus or drug-induced Par-
kinsonism, except if persisting following discontinuation
of the causative drug.
Assessments (see Table 1) are conducted in person at
baseline and at 12 months, with optional telephone
follow-up at 6 and 18 months.
Interventional trial
Inclusion criteria
For the interventional trial, patients are eligible if they
experience at least one of the following insufficiently
treated symptoms/problems (based on clinical judg-
ment): motor parkinsonism according to Unified Parkin-
son’s Disease Rating Scale (UPDRS; including nocturnal
motor problems), levodopa-induced motor complica-
tions, including Off-time > 50% of waking day (assessed
on UPDRS part IV), moderately disabling dyskinesias
(item 33 ≥ 2) or Off time dystonia, PD dementia (defined
according to MDS Task Force definition [18], depression
(GDS > 4 points) not receiving adequate treatment,
psychotic symptoms, agitation/ aggression; anxiety and
irritability/ liability (all NPI items > 4 points), symptom-
atic orthostatic hypotension, pain, constipation, urinary
symptoms, insomnia or daytime sleepiness, falls OR are
treated medications potentially associated with exacerba-
tion of PD-related problems: (a) typical antipsychotics
other than quetiapine or clozapine, anticholinergics,
benzodiazepines, pills with protein rich meal, antihyper-
tensives in symptomatic hypotensive patients, valproate,
calcium antagonists, other medications with side effect
exacerbating PD motor or non-motor symptoms OR are
at risk of contractures and skin ulceration OR inad-
equate management of dysphagia with risk of choking,
of dysarthria or of hypersalivation OR live in an inad-
equate home environment.
Exclusion criteria
Patients with parkinsonism seen by a movement disor-
ders specialist in the four months prior to inclusion, and
patients unable to comply with management plans (such
as attending physiotherapy or change of medication) are
excluded from the intervention trial.
Participants fulfilling the inclusion criteria are rando-
mised in an open-label trial to two-arms in 3:1 allocation:
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to an intervention or care as usual, and assessed at
6 months (in-person; primary outcome) and optionally at
12 and 18 months (telephone review, secondary outcome).
The intervention consists of individually tailored treat-
ment strategies suggested by specialists after review of the
baseline assessment and treatment regime.
Qualitative study
Inclusion criteria
For the qualitative study, approximately 10 PD patients and
an informal carer in each participating center (London, UK,
Lund, Sweden, and Lisbon, Portugal) are being recruited
consecutively. For inclusion, the same criteria apply as for
the cohort study.
Exclusion criteria
In addition to the exclusion criteria of the cohort study,
patients unable to communicate in words (because of ei-
ther dysarthria or language problems) are excluded from
the qualitative study.
Semi-structured interviews with patients and informal
carers are conducted on the needs of patients with late
stage Parkinsonism. The questions addressed are: per-
ceived met and unmet needs, including palliative care
Table 1 Assessment instruments and time points of application
Scales/Domains Instruments Reference Application at
T1 T2 T3 T4
Patient-completed
Quality of life and health status EuroQol instrument [20] x x (x) (x)
PDQ-8a [21] x x x x
Meaning in Life SMiLE [22] x x (x) (x)
Satisfaction with Care Likert scale x x (x) (x)
Carer-completed
Quality of life and health status EuroQol instrument [20] x x (x) (x)
Patient Quality of Life DEMQOL-Proxyb [23] x x x x
Satisfaction with Support Likert Scale x x (x) (x)
Caregiver burden Zarit burden scale [24] x x (x) (x)
Clinician-completed
Activities of daily living UPDRS (pt. II) [25] x x x x
Schwab&England [16] x x x x
Demographic/social data x
Checklist of symptoms, treatments, tests
Comorbidities Charlson-Index [34] x x (x) (x)
Resource Utilisation questionnaire [19] x x x
Clinical rating/judgement CGI [26] x x x x
Hoehn and Yahr [8] x x (x) (x)
UPDRS (pts. I, III, IV) [25] x x (x) (x)
Cognitive assessment MMSE+clock drawing+fluency [27–29] x x (x) (x)
Pill questionnaire [18] x x (x) (x)
Neuropsychiatric and other non-motor symptoms Neuropsychiatric Inventory (NPI-12) [30] x x (x) (x)
Non-motor symptom scale [31] x x x x
Geriatric Depression Scale (GDS) [32] x x (x) (x)
Basic palliative assessment ESAS-(PD) [33] x x (x) (x)
Supine and standing blood pressure x
Evaluation of Implementation x
ain patients with a diagnosis Parkinson’s disease only; bin patients with dementia instead of PDQ8 and EQ-5D; (×) optional; T1 = Baseline with randomisation, T2:
6 months after baseline (in-person for intervention participants only), T3: 12 months after baseline (telephone with patient and/or carer or optional in-person
assessment), and T4: 18 months after baseline (telephone with patient and/or carer or optional in-person assessment). Abbreviations used: PDQ-8 The Parkinson’s
Disease Questionnaire, short form, SMiLE Schedule for Meaning in Life Evaluation. Euroqol-Instrument (EQ-5D Index and visual analogue scale), DEMQOL-Proxy
health-related quality of life for people with dementia - proxy version. CGI Clinical Global Impression, UPDRS Unified Parkinson’s Disease Rating Scale, UPDRS
Unified Parkinson’s Disease Rating Scale, MMSE Mini Mental State Examination, ESAS-PD Edmonton Symptom Assessment System – Parkinson’s Disease
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needs, the experience and perceived impact of receipt of
services, formal and informal support, exploration of
deficits and barriers to adequate care provision, identifi-
cation of factors influencing the decision as to whether
patients are cared for at home or in residential care/in-
stitution, and advanced care planning (attitudes of pa-
tients towards advance directives and preferred place of
death). These interviews are audio-recorded and tran-
scribed; and then subject to thematic analysis aided by
the N-VIVO computer program to identify the range of
experiences and perceived needs and outcomes of differ-
ent services provisions and treatments.
Recruitment strategies
The major challenge in the CLaSP project is the identifica-
tion, recruitment, and assessment of patients in late
stages. We particularly aim to include patients who are
not under regular specialist follow-up. Therefore, several
methods to reach this target group are employed, particu-
larly aiming to recruit individuals not currently attending
routine specialist clinics: The centers contacted general
practitioners, hospitals, nursing homes, patient advocate
groups as well as self-help groups to draw attention to the
CLaSP project and identify and recruit eligible patients.
Clinical assessment
Cohort study
The assessment of patients and carer comprise of standar-
dised questionnaires to evaluate disease severity, comor-
bidities, depression, cognition, non-motor symptoms,
quality of life in patients and carers as well as caregiver
burden (for an overview of timepoints and instruments/
questionnaires applied, see Table 1). The patients of the
cohort study are followed up in person at 12 months and
optionally via telephone at 6-month and 18 months. A
special resource use questionnaire for patients with Par-
kinson’s disease and their carers was developed and used
in a previous health economic cost of illness study [19]
was applied. The questionnaire was adapted to the re-
quirements of the respective country-specific health care
system.
Intervention study
Baseline assessments are repeated at 6 months (T2) in
person and on the telephone at 12 months. In addition,
at T2, information is collected whether the individual
intervention has been implemented into the patient’s
treatment schedule.
Outcome measures
The following instruments are used to collect data on
the patients and their caregivers at different time points
during the study (see also Table 1):
Health-related quality of life in PD patients and their
caregivers is evaluated using the self-completed, generic
EuroQol instrument, which comprises a questionnaire
(EQ-5D) and a visual analogue scale (EQ VAS) [20]. The
questionnaire consists of five questions with three levels
of possible answers, representing the dimensions Mobility,
Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/
Depression. In the EQ VAS, the participants rate their
subjective health status on a scale with a range of 0 to 100
with higher scores indicating a better quality of life. Add-
itionally, the self-administered, disease-specific PDQ-8
instrument is used in patients [21]. It is derived from the
PDQ-39 and assesses eight domains: Activities of Daily
Living, Attention and Working Memory, Communication,
Depression, Quality of Life, and Social Relationships.
Higher scores in the PDQ-8 indicate more problems and a
worse quality of life. Satisfaction with Care is assessed in
the patient via a 5-point Likert scale, with higher rating
reflecting less satisfaction. The Schedule for Meaning in
Life Evaluation (SMiLE) is an instrument to assess individ-
ual meaning in life [22]. First, the patients list one to seven
areas that provide meaning to their lives and subsequently
rate the current level of importance and satisfaction of
each area. From these answers, a sum score can be calcu-
lated where higher scores indicate higher satisfaction in
life. The DEMQOL proxy is used to obtain caregiver re-
ports on the patient’s quality of life [23]. In our study, it is
applied in patients with dementia instead of the
PDQ-8 and the Euroqol instrument. Satisfaction with Sup-
port is assessed in the caregiver via a 5-point Likert scale,
with higher rating indicating less satisfaction. The care-
giver burden is assessed via the revised 22-items version
of the Zarit Burden Scale [24]. Each item on the interview
is answered by the caregiver on a 5-point scale with higher
sum scores reflecting higher burden on the caregiver. The
clinician completes the following assessments on the
patient: For the clinical evaluation of Parkinson’s disease,
the Unified Parkinson’s disease Rating Scale (UPDRS) is
used to assess patients in four sections: Mentation,
Behavior and Mood, Activities of Daily Living, Motor
Examination, and Complications of Therapy [25]. In
addition, the Hoehn and Yahr scale (HY) is used to describe
the stage of PD severity [8]. The patient’s ability to perform
activities of daily living is assessed with the Schwab &
England Scale [16]. The score reflects the patient’s situation
on a 0 (= complete dependence/bedridden) to 100% (=
complete independence) scale. The Clinical Global Impres-
sion (CGI) rating scale is used to evaluate the patients’
symptom severity and change of symptoms over time [26].
The Mini-Mental State Examination (MMSE) is an assess-
ment tool for general cognitive impairment, with higher
overall total scores (range 0–30) indicating better perform-
ance [27]. The clock-drawing test is used for screening for
cognitive impairment and dementia [28], which is sensitive
Balzer-Geldsetzer et al. BMC Neurology          (2018) 18:185 Page 4 of 8
to visuo-spatial impairment. The verbal fluency test (letter
s) is used as a short test of executive function [29]. The Pill
Questionnaire is a screening tool for mild cognitive impair-
ment in nondemented Parkinson’s disease patients, using
the ability to remember Parkinson’s disease-specific medi-
cations as an indicator of cognitive function [18]. The
Neuropsychiatric Inventory (NPI-12) is an informant-based
instrument to assess the presence and severity of twelve
neuropsychiatric symptoms (i.e. delusions, hallucinations,
agitation/aggression, dysphoria/depression, anxiety, eu-
phoria/elation, apathy/indifference, disinhibition, irritabil-
ity/lability, aberrant motor behaviors, night-time behavioral
disturbances, appetite/eating disturbances) in patients with
dementia, as well as informant distress [30]. To assess the
occurrence and severity of non-motor symptoms, the
Non-Motor Symptom Scale (NMSS) is used [31]. The
Geriatric Depression Scale (GDS) is a 15-item screen-
ing tool with higher overall total scores (range 0–15)
indicating higher depression levels [32]. The modified
Edmonton Symptom Assessment System Scale for PD
(ESAS-PD) was modified from symptom assessment in
palliative care for patients with PD [33]. Comorbidities
are assessed with the Charlson Comorbidity Index
(CCI) [34].
Primary endpoint
The primary endpoint is the absolute change in UPDRS-
ADL score from baseline to month 6 (intervention study)
and to month 12 (cohort study). The UPDRS is adminis-
tered by a researcher blinded to the treatment group.
Secondary endpoints
Secondary endpoints are the patients’ quality of life,
mental health, disease severity and disability, non-motor
symptoms scale score, occurrence of disease severity
milestones (psychosis, dementia, falls, wheelchair-bound,
institutionalization, and death), satisfaction with care as
well as caregiver burden.
Ethical approval
The CLaSP study is being conducted in compliance with
the Helsinki Declaration [35], i.e. detailed oral and written
information is given to the patients and their informant to
ensure that the patient fully understands potential risks
and benefits of the study. The study protocol was ap-
proved by the local ethics committees of all participating
study sites (London:Camden and Islington NRES Com-
mittee 14/LO/0612, Bordeaux: South West and Overseas
Protection Committee III (South West and Overseas Pro-
tection Committee). 2014-A01501–46, Lisbon:Centro
Hospitalar Lisboa Norte, DIRCLN-19SET2014–275, Lund:
EPN Regionala etikprovningsnamnden: Lund (EPN Re-
gional Ethics Name: Lund). JPND NC 559–002, Marburg:
Ethik-Kommission bei der Landesarztekammer Hessen
(Ethics Commission at the State Medical Association
Hesse). MC 309/2014, Munich: Ethikkommission bei der
LMU Munchen (Ethics committee at the LMU Munchen).
193–14, Nijmegen: Radboud universitair medisch centrum,
Concernstaf Kwaliteit en Veiligheid, Commissie Mensge-
bonden Onderzoek Regio Arnhem-Nijmegen (Radboud
university medical center,Group staff Quality and Safety
Human Research Committee, Arnhem-Nijmegen region).
DJ/CMO300).
Informed consent
Participants (patients and their caregivers) are included
in the study after giving their written informed consent.
In case the patient lacks capacity to give consent to the
study due to severe cognitive impairment, the decision
on study participation is made by a legal guardian or
consultee, depending on the ethical and legal require-
ments at each site. All participants (patients and care-
givers) can withdraw from the study at any point in time
without any negative implications.
Sample size
For the baseline evaluation of the Cohort study, at least 70
patients will be recruited per country. Out of this sample,
48 patients per country will be randomised for the inter-
vention study. Permuted block randomization is used,
stratified by country, dementia (yes/ no) and residence
(nursing home or similar/ home). Applying a one-way
ANOVA at a significance level of 5% and power of 80%, a
sample size of 70 per country allows to detect differences in
UPDRS-ADL scores between health care systems with a
standard deviation of means of 1.76. The common standard
deviation within each county is assumed to be 10.
For the Intervention study, the power calculations
were based on the analysis of the primary efficacy end-
point: absolute change in UPDRS-ADL (Unified Parkin-
son’s Disease Rating Scale – part II, activities of daily
living) score from baseline to month 6 (time to complete
the intervention). Assumptions for mean and standard
deviation of change in UPDRS-ADL scores of the inter-
vention group are based on results of a previous study
using the UPDRS-ADL [36]. An independent sample
t-test was used to determine the sample size needed for
detecting a difference in change of 4.8 between the two
treatment groups. Assuming a standard deviation of 10
for difference in change, a two-sided significance level of
5%, a power of 80%, and non-participating and dropout
rates of 20% each, 216 patients were calculated to be
needed for the intervention group and 72 patients to the
standard group (3:1 allocation).
Statistical analysis
Categorical variables will be analysed by absolute and rela-
tive frequency, continuous variables by median, mean,
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standard deviation, 95% confidence interval, minimum,
and maximum. Differences in continuous variables be-
tween groups (e.g. countries) at time points will be tested
by analysis of variance (ANOVA) and analysis of covari-
ance (ANCOVA) or their nonparametric analogues, re-
spectively. Differences between groups at time points
assessed by proportions will be analysed by the Chi-square
or Fisher’s exact test, if applicable, and logistic regression.
Changes in continuous variables between two time
points will be evaluated by the paired t-test or Wilcoxon
signed rank test, respectively. Changes in proportions
between two time points will be analysed by the McNe-
mar test. Longitudinal analyses will be performed by ap-
plying linear and generalized linear mixed models with
patient or carer as random effect, main effects for coun-
try and time, as well as a country-by-time interaction
term and possible confounders.
In the intervention study, all analyses of outcome
parameters will be done in the intent-to-treat popula-
tion. The primary efficacy analysis will be to investigate
the treatment effect on absolute change in UPDRS-ADL
score from baseline to month 6 in the intervention and
standard care group. Data will be analyzed using
ANCOVA with categorical factors (treatment, country,
dementia, residence) and baseline UPDRS-ADL score as
a covariate. The null hypothesis “no difference in the
primary endpoint between the intervention group and
standard care group” will be tested against the alterna-
tive hypothesis “difference in the primary endpoint be-
tween both groups”. The primary efficacy analysis will
be repeated using the per-protocol population to con-
firm the overall study results. Safety data will be ana-
lyzed in the as-treated population.
All tests will be performed two-sided, p values < 0.05
will be considered statistically significant.
Discussion
Despite a large variety of symptomatic and supportive
treatment options, PD remains a progressive and ultim-
ately very disabling disorder, for which as yet no
disease-modifying drugs exist. With the increasing popu-
lation age and rising prevalence of PD expected over the
next decades there is a growing challenge in the appro-
priate care for patients who reach the late stages of this
disorder [37]. Improvements in care of late stage Parkin-
sonism are likely not only to improve patients’ health-re-
lated quality of life and caregiver burden, but also to
reduce health care costs substantially by reducing the
rate of institutionalization, hospital admissions, and
polypharmacy. The CLaSP study is the first study that
specifically characterises the clinical features, comorbidi-
ties, health care and social care needs, current treatment
strategies and outcomes of patients with late stage par-
kinsonism across several European countries. It will
evaluate the impact on patients as well as their carers,
identify the current provision of health care and how it
meets these needs, evaluate the adequacy of standard
assessment methods and examine whether specialised,
tailored review improves outcomes in patients with par-
kinsonism. It will also provide essential information on
health economic data on the costs of providing health
and social care for patients with this condition. Combin-
ing the cohorts' detailed assessments, using quantitative
and qualitative data, in six different countries and across
neurology, geriatric and palliative care settings, and
studying this cohort longitudinally, will provide multifa-
ceted, in-depth knowledge on this little studied popula-
tion. This information can then inform how best to
provide effective and cost-effective health and social care
for this severely affected patient group and contribute to
improved practices for clinical care.
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